COMPARATIVE STUDY OF INTRAVENOUS IRON SUCROSE VS ORAL FERROUS SULFATE THERAPY FOR UNCOMPLICATED IRON DEFICIENCY ANEMIA

JAHAN D1, ISLAM MM 2, HOSSAIN MZ3, SALSABIL MA4, ISLAM I5, HUQUE AKMZ6, KARIM ME7, MAZUMDER8, KHAN MA9

Abstract:
Background: Iron deficiency anemia (IDA) is one of the most frequent nutritional deficiency leading to morbidity and mortality in whole world. Oral iron therapy as well as intravenous (IV) iron therapy can be given to treat the IDA patients.

Objective: To compare the efficacy and hematological changes of Oral and IV iron preparation in patients with uncomplicated iron deficiency anemia.

Method: An interventional, prospective study in patients with uncomplicated IDA anemia receiving IV iron sucrose and Oral iron ferrous sulfate were included. Clinical history, baseline hemoglobin, anemia indices data were recorded in a case record form. A total number of 80 patients were enrolled in this study. 40 patients (Group A) were treated with IV iron sucrose and another 40 patients (Group B) were treated with oral iron ferrous sulfate. After therapy Hemoglobin level, RBC indices and adverse drug reactions (ADRs) were observed.

Place and period of Study: Study was carried out in the Department of Hematology at Dhaka Medical College Hospital (DMCH), from July 2015 to June 2016.

Results: The mean age of total participants was 35.77 ± 16.08 (range of 13 – 75 years). In this study female (72.5%) is predominant than male (27.5%). Oral and IV iron preparations significantly (P<0.0001) improved mean hemoglobin, anemia indices at the end of study. However, mean increase in hemoglobin were significant (P<0.0001) with IV iron sucrose (7.6 ± 2.9) gm/dl, as compared to Oral ferrous sulfate (6.4± 2.2)gm/dl, after 2 months of therapy. In this study Hemoglobin increases in group A (IV iron arm) almost 1mg/kg/week and in group B (oral iron arm) 0.8 mg/dl/week).Surprisingly, ADRs were more in patients treated with oral ferrous sulfate (38%) compared to iron sucrose (26%).

Conclusion: IV iron sucrose improves hemoglobin, anemia indices and replenish iron stores rapidly and is well tolerated than oral iron preparations.

Key words: Iron deficiency anemia, Intravenous iron sucrose, Hemoglobin concentration.

J Dhaka Med Coll. 2018; 27(2) : 175-181

Introduction:
Iron deficiency is the most common nutritional deficiency in the world1. In the United States iron deficiency most commonly occurs in toddlers, adult and adolescent fe males1,2. Patients with iron deficiency anemia (IDA) may be asymptomatic, or may have signs and symptoms such as headache, fatigue, tachycardia, exertional tachypnea2.

One of the most common causes of iron deficiency in adult Americans is acute blood loss, like gastrointestinal (GI) bleeding, trauma,
surgery and postpartum bleeding, other causes include malnutrition, decreased iron absorption, celiac disease, use of erythroid stimulating agents (ESAs), chronic illness, gastric bypass surgery, and congenital iron deficiency. IDA is associated with an increased susceptibility to infections, decreased work productivity and slower cognitive and motor development in children. In addition, there is an association between low hemoglobin and preterm birth as well as lower birth weight.

The available intravenous iron formulations include iron dextran, iron sucrose, sodium ferric gluconate and iron carboxymaltose. Iron sucrose and sodium ferric gluconate seem to have a lower incidence of anaphylaxis, can safely given in small dosages or as an infusion of larger dosages. For past half a century, the standard therapy for iron deficiency anemia has been ferrous salts. Ferrous sulfate and gluconate are effective in the correction of iron deficiency anemia, though prolonged duration of treatment is required to correct anemia and replenish iron stores, it is cheap and no history of anaphylactic reaction.

So, the present study was done to compare the hematological response and observe ADRs after therapy with IV iron sucrose and oral iron ferrous sulfate therapy in uncomplicated iron deficiency anemia.

Material And Methods:
Study design, study setting and study period:
This interventional, prospective study was carried out in the Department of Hematology at Dhaka Medical College Hospital (DMCH), conducted from July 2015 to June 2016 for a period of one (01) year.

Study participants, sample size, sampling:
Study participants were classified in two groups. Total 80 study population were taken purposively. 40 patient is in group A at any age, diagnosed as iron deficiency anemia with hemoglobin <9 gm/dl, given IV iron sucrose with an optimum duration of therapy of 01 to 02 weeks. Another 40 patient in group B with hemoglobin <9 gm/dl, treated with oral iron ferrous sulfate for consecutive 2 months.

Exclusion criteria: a) Anemia not linked to iron deficiency. b) History of asthma, thromboembolism, seizures or drug abuse. c) Signs of infection or evidence of renal or hepatic dysfunction

Methods of data collection: The study participants were selected from indoor and outpatient hematology department of DMCH after fulfilling the selection criteria. After careful history taking, clinical examination and minimal investigations for other causes of anemia were ruled out. The initial iron status was assessed by the clinical and laboratory examinations (complete blood picture, reticulocyte count and serum iron profile). Who are fulfilling above criteria were included in the study. They were randomly divided into two groups. For group A, the amount of IV iron needed by an individual is calculated by the following formula.

Body weight (kg) × 2.3 × (15-patient’s hemoglobin, g/dl) +500 or 1000 mg (for stores).

For group B oral ferrous sulfate given 200 mg (65 mg elemental iron) twice daily for 2 months (total elemental iron 3900 mg X 2 months).

All patients are randomly enrolled for group A and group B in this study. Prior to the commencement of this study, the research protocol was approved by the ethical committee of the Dhaka Medical College Hospital, Dhaka. Informed consent was taken from the participants prior to interview.

Adverse effects were observed after therapy like dyspepsia, diarrhea, local discomfort, skin rash, fever, headache, arthralgia, hypertension, lymphadenopathy, anaphylactic reactions, hypotension, body pain and others. The follow up schedule was before therapy, 2 weeks, 1 month and 2 months after therapy.

Statistical analysis: All data were recorded systematically in preformed data collection form (questionnaire) and quantitative data was expressed as mean and standard deviation and qualitative data was expressed as frequency distribution and percentage. Statistical analysis was performed by using Microsoft Office Excel 2016. Probability value (P) <0.05 was considered as level of significance.
Results

### Table-I

**Age & Sex distribution of the respondents**

| Parameter | Mean± SD     | Range (years) |
|-----------|--------------|---------------|
| Age       | 35.77 ± 16.08| 13-75         |
| Sex       |              |               |
| Male      | 22           | 27.5          |
| Female    | 58           | 72.5          |

### Table-III

**Response of Peripheral Blood Film (PBF) before and after iron therapy in Both A and B group**

| PBF Findings          | Before Therapy | 2 weeks After Therapy | 1 month After Therapy | 2 months After Therapy |
|-----------------------|----------------|-----------------------|-----------------------|------------------------|
| Iron deficiency anemia|                |                       |                       |                        |
| Dimorphic anemia      |                |                       |                       |                        |
| Normal Study          |                |                       |                       |                        |
| Normal Study          |                |                       |                       |                        |

### Table-IV

**Changes of Hemoglobin and RBC count after IV iron therapy**

| Hemoglobin (gm/dl) | Therapy               | Mean ± SD | Range (Min – Max) |
|--------------------|-----------------------|-----------|-------------------|
|                    | Before Therapy        | 6.3 ± 1.1 | 4.60 - 8.70       |
|                    | 2 weeks After Therapy | 9.4 ± 1.4 | 7.20 - 11.70      |
|                    | 1 month After Therapy | 12.6 ± 0.5| 11.60 - 14.20     |
|                    | 2 months After Therapy| 13.9 ± 0.7| 12.10 - 15.70     |
| RBC (number x 10^{12}/L) | Before Therapy     | 2.9 ± 0.2 | 2.07 - 3.01       |
|                    | 2 weeks After Therapy| 3.3 ± 0.9 | 2.81 - 3.40       |
|                    | 1 month After Therapy| 3.9 ± 0.1 | 3.40 - 4.01       |
|                    | 2 months After Therapy| 4.7 ± 0.5| 4.03 - 5.94       |

Data was expressed as Mean ± SD

### Table-V

**Changes in Hemoglobin and RBC count after Oral iron therapy**

| Hemoglobin (gm/dl) | Therapy               | Mean ± SD | Range (Min – Max) |
|--------------------|-----------------------|-----------|-------------------|
|                    | Before Therapy        | 6.4 ± 1.5 | 4.30 - 8.80       |
|                    | 2 weeks After Therapy | 7.9 ± 0.7 | 6.90 - 9.10       |
|                    | 1 month After Therapy | 10.4 ± 0.6| 9.20 - 11.20      |
|                    | 2 months After Therapy| 12.0 ± 0.6| 11.10 - 13.22     |
| RBC (number x 10^{12}/L) | Before Therapy     | 2.1 ± 0.07| 2.01 - 2.21       |
|                    | 2 weeks After Therapy| 2.6 ± 0.2 | 2.31 - 2.80       |
|                    | 1 month After Therapy| 3.4 ± 0.2 | 3.10 - 3.71       |
|                    | 2 months After Therapy| 4.1 ± 0.2| 3.91 - 4.40       |

Data was expressed as Mean ± SD
### Table VI

*Response of RBC indices after IV iron and Oral iron therapy*

| MCV (fl)      | Therapy                      | Mean ± SD  | Range (Min - Max) |  
|---------------|------------------------------|------------|-------------------|  
| Before Therapy| 63.6 ± 4.8                   | 58.00 - 71.00 |  
| 2 weeks After Therapy | 72.9 ± 3.6                   | 66.20 - 76.10 |  
| 1 month After Therapy | 79.0 ± 2.7                   | 75.10 - 82.30 |  
| 2 months After Therapy | 81.9 ± 2.4                   | 78.40 - 86.30 |  
| MCH (pg)      | Before Therapy               | 16.8 ± 1.6  | 12.60 - 18.20 IV iron  
| 2 weeks After Therapy | 22.5 ± 2.2                   | 18.70 - 25.01 sucrose |  
| 1 month After Therapy | 26.6 ± 1.5                   | 25.10 - 30.02 |  
| 2 months After Therapy | 28.8 ± 1.6                   | 27.01 - 33.03 |  
| MCHC (g/dl)   | Before Therapy               | 26.5 ± 1.9  | 21.10 - 28.00 |  
| 2 weeks After Therapy | 29.6 ± 1.5                   | 26.10 - 31.70 |  
| 1 month After Therapy | 31.4 ± 1.5                   | 28.40 - 34.00 |  
| 2 months After Therapy | 32.7 ± 0.7                   | 32.10 - 36.10 |  
| MCV (fl)      | Before Therapy               | 66.4 ± 4.5  | 59.00 - 72.00 |  
| 2 weeks After Therapy | 71.6 ± 2.0                   | 68.20 - 74.10 |  
| 1 month After Therapy | 77 ± 1.9                     | 74.10 - 80.30 |  
| 2 months After Therapy | 79.3 ± 1.8                   | 76.40 - 82.30 |  
| MCH (pg)      | Before Therapy               | 15.7 ± 0.8  | 14.60 - 17.20 Oral iron  
| 2 weeks After Therapy | 21 ± 2.1                     | 17.70 - 24.01 ferrous |  
| 1 month After Therapy | 25.8 ± 1.2                   | 24.10 - 28.02 sulfate |  
| 2 months After Therapy | 28.6 ± 1.6                   | 26.01 - 32.03 |  
| MCHC (g/dl)   | Before Therapy               | 22.6 ± 1.7  | 20.10 - 25.00 |  
| 2 weeks After Therapy | 24.9 ± 2.2                   | 22.10 - 28.70 |  
| 1 month After Therapy | 28.6 ± 1.2                   | 26.40 - 30.30 |  
| 2 months After Therapy | 29.8 ± 1.2                   | 28.10 - 32.10 |  

Data was expressed as Mean ± SD
Table VII

Changes of Hemogram before and 60 days after therapy with IV iron

| Hemogram | Before Therapy | 60 days after therapy | p-value |
|----------|----------------|-----------------------|---------|
| HB       | 6.3 ± 1.1      | 13.9 ± 0.7            | .001    |
| RBC      | 2.9 ± 0.2      | 4.7 ± 0.5             | .001    |
| MCV      | 63.6 ± 4.8     | 81.9 ± 2.4            | .001    |
| MCH      | 16.8 ± 1.6     | 28.8 ± 1.6            | .001    |
| MCHC     | 26.5 ± 1.9     | 32.7 ± 0.7            | .001    |

p value 0.001

Table-VIII

Changes in Hemogram before and 60 days after therapy with oral iron

| Hemogram | Before Therapy | 60 days after therapy | p-value |
|----------|----------------|-----------------------|---------|
| HB       | 6.4 ± 1.5      | 12.0 ± 0.6            | .001    |
| RBC      | 2.1 ± 0.07     | 4.1 ± 0.2             | .001    |
| MCV      | 66.4 ± 4.5     | 79.3 ± 1.8            | .001    |
| MCH      | 15.7 ± 0.8     | 28.6 ± 1.6            | .001    |
| MCHC     | 22.6 ± 1.7     | 29.8 ± 1.2            | .001    |

p value 0.001

Discussion:
Iron is critical for the growth of all human cells, that’s why IDA independently increases morbidity and mortality significantly\(^1\). There are an estimated 3.5 billion iron deficient people worldwide, the vast majority is in developing countries and remarkably, iron deficiency is also the most common cause of anemia in the United States\(^2\). This study Intravenous iron sucrose was given to group A participants and oral iron ferrous sulfate was given to group B participants.
In this study, the mean age of the respondents was 35.77 ± 16.08 which ranges from 13 – 75 years (Table-1). Similar result was published by Zhu et al. (2010)\textsuperscript{11} and Edward Litton et al. (2013)\textsuperscript{12}, mentioned that IDA remains extremely common in the adult population.

Regarding sex, females were 72.5% and males were 27.5% (Table-1) which indicates females were predominant than male. Similar finding was supported by Alleyne et al. (2008)\textsuperscript{13}, Ho et al (2008)\textsuperscript{14}, these studies explained the reason and mentioned that females generally have lower levels of iron than males because of the iron is lost during menses, pregnancies and lactation and detected that IDA is more prevalent among female which is consistent with the present study.

Another similar study done by Alleyne et al., hemoglobin was different for patients in the oral iron and IV iron sucrose groups across time in each individual group as well as at any given point of time. The hemoglobin level was significantly higher in the IV iron sucrose group\textsuperscript{13}. Iron sucrose is costlier than Oral iron and requires a hospital setting for administration\textsuperscript{15}. Al Momen et al., observed that the intravenous iron sucrose (group A) achieved significantly higher hemoglobin level ($P$ value $\leq 0.001$) in a shorter period ($P$ value $\leq 0.001$)\textsuperscript{15}.

The mean hemoglobin concentration in group A (IV iron arm) before therapy was $6.3 \pm 1.1$ with a range of $4.60 - 8.70$ gm/dl and two month after therapy the mean hemoglobin concentration was $13.9 \pm 0.7$, with a range of $12.10$ to $15.70$ gm/dl. The mean Hemoglobin concentration in group B (Oral iron arm) before therapy was $6.4 \pm 1.5$ with a range of $4.30$ to $8.80$ gm/dl and two month after therapy the mean hemoglobin concentration was $12.0 \pm 0.6$ with a range of $11.10$ to $13.22$ gm/dl.

The study by Breymann C et al. showed a mean rise in the hemoglobin level was $1.7$ g/dl, 25 days after the iron sucrose therapy. Also a study by Wali et al. showed the hemoglobin level rise of $2.6$ g/dl after 3.6 weeks\textsuperscript{16}. Similar result was reported by Alleyne et al (2008)\textsuperscript{13} and mentioned that patients with iron deficient anemia should manifest a response to iron by an increase in hemoglobin in 2-4 weeks. The study also added that theoretically, 500 mg of absorbed iron should produce 500 cc of packed cells, the amount in about 2 units of blood, or raise the hemoglobin about 2 g/dL.

**Conclusion:**

Though Oral Iron preparation is safe but associated with gastric side effects resulting in poor compliance. In group B more than 30% of participants stop iron intake due to related side effects. Several studies have proved the safety & efficacy of iron sucrose, it is tolerated well & has no major side effects, therefore can be used as a substitute for oral preparations \textsuperscript{17, 18}. In our study there were no major side effects with iron sucrose & had better compliance so can be safely used in any age and an alternative to blood transfusion in the treatment of severe iron deficiency anemia. Yet larger trials are required to conclude that parental preparation can be substituted for oral preparations.

**Acknowledgements:**

Department of Hematology, DMCH, Prof (Dr.) Salma Afrose, Asso. Prof (Dr.) Tasneem Ara

**References :**

1. Castro RS, Irwin C, Moriarity-Suggs C. Diagnosis and management of iron deficiency anemia.Ca J Health Sys Pharm. 2010;2:5-14.

2. Centers for Disease Control and Prevention (CDC). Iron deficiency – United States, 1999–2000. MMWR. 2002; 51:897–899

3. Strauss RG. Iron deficiency, infections and immune function: a reassessment. Am. J. Clinical Nutrition. 2004; 79(3):516-521.

4. Haas JD, Brownie T. Iron deficiency and reduced work capacity: a critical review of the research to determine a causal relationship. J Nutr. 2001;131(2):676S—690S

5. Grantham-McGregor S, Ani C. A review of studies on the effect of iron deficiency on cognitive development in children. J Nutr. 2001;131(2s-2):649S—668S

6. Rasmussen KM. Is there a causal relationship between iron deficiency or iron deficiency anaemia and weight at birth, length of gestation and perinatal mortality. J Nutr. 2001; 131:590S—603S

7. Spinowitz BS, Kausz AT, Baptista J, Noble SD, Sothinathan R, Bernardo MV, Brenner L, Pereira BJG. Ferumoxytol for Treating Iron Deficiency Anaemia in CKD. J Am Soc Nephrol. 2008:19: 1599–1605
8. Fishbane S: Safety in iron management. Am J Kidney Dis 2003; 41: 18–26
9. Chertow GM, Mason PD, Vaage-Nilsen O, Ahlmen J: Update on adverse drug events associated with parenteral iron. Nephrol Dial Transplant 2006; 21: 378–382
10. Gordeuk VR, Brittenham GM, McLaren CE, Hughes MA, Keati LJ. Carbonyl Iron Therapy for Iron Deficiency Anaemia Blood. 1986; 67(3):745-752
11. Zhu, A., M. Kaneshiro, and J. Kaunitz. Evaluation and Treatment of Iron Deficiency Anaemia: A Gastroenterological Perspective. Digestive Diseases and Sciences, 2010; 55(3): p. 548-559
12. Edward Litton, Jing et al. Safety and efficacy of intravenous iron therapy in reducing requirement of allogeneic blood transfusions. Systemic review and meta-analysis of RCT. BMJ.2013; 347:4822.
13. Alleyne M, Horne MK, Miller JL. Individualized treatment for iron deficiency anaemia in adults. Am J Med. 2008; 121(11): 943–948
14. Ho CH, Yu YB, Wu PH. The prevalence of iron deficiency anaemia and its clinical implications in patients with colorectal carcinoma. J Chin Med Assoc. 2008; 71:119–122
15. al-Momen AK, al-Meshari A, al-Nuaim L, Saddique A, Abotalib Z, Khashogii T, et al. Intravenous iron sucrose complex in the treatment of iron deficiency anemia during pregnancy. Eur J Obstet Gynecol Reprod Biol. 1996; 69:121–4.
16. Breymann C, Perewusnyk G, Huch R, Huch A. Parenteral iron therapy in obstetrics: 8 years experience with iron-sucrose complex. Br J Nutr 2002;88:3-10.
17. Dhanani J V., Ganguly B P, Chauhan L N. Comparison of efficacy and safety of two parenteral iron preparations in pregnant women. Journal of Pharmacology and Pharmacotherapeutics. 2012;3(4): 314-19
18. Patel J , Patel K , Patel J , Sharma A , Date SK. Comparison of Intravenous Iron Sucrose and Ferric Carboxymaltose Therapy in Iron Deficiency Anemia during Pregnancy and Postpartum Period. JPSBR; 3:2015; 5(3):139-243.